Gene expression and epigenetic discovery screen reveal methylation of SFRP2 in prostate cancer
Open Access
- 23 August 2012
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 132 (8), 1771-1780
- https://doi.org/10.1002/ijc.27798
Abstract
Aberrant activation of Wnts is common in human cancers, including prostate. Hypermethylation associated transcriptional silencing of Wnt antagonist genes SFRPs (Secreted Frizzled‐Related Proteins) is a frequent oncogenic event. The significance of this is not known in prostate cancer. The objectives of our study were to (i) profile Wnt signaling related gene expression and (ii) investigate methylation of Wnt antagonist genes in prostate cancer. Using TaqMan Low Density Arrays, we identified 15 Wnt signaling related genes with significantly altered expression in prostate cancer; the majority of which were upregulated in tumors. Notably, histologically benign tissue from men with prostate cancer appeared more similar to tumor (r = 0.76) than to benign prostatic hyperplasia (BPH; r = 0.57, p < 0.001). Overall, the expression profile was highly similar between tumors of high (≥ 7) and low (≤ 6) Gleason scores. Pharmacological demethylation of PC‐3 cells with 5‐Aza‐CdR reactivated 39 genes (≥ 2‐fold); 40% of which inhibit Wnt signaling. Methylation frequencies in prostate cancer were 10% (2/20) (SFRP1), 64.86% (48/74) (SFRP2), 0% (0/20) (SFRP4) and 60% (12/20) (SFRP5). SFRP2 methylation was detected at significantly lower frequencies in high‐grade prostatic intraepithelial neoplasia (HGPIN; 30%, (6/20), p = 0.0096), tumor adjacent benign areas (8.82%, (7/69), p < 0.0001) and BPH (11.43% (4/35), p < 0.0001). The quantitative level of SFRP2 methylation (normalized index of methylation) was also significantly higher in tumors (116) than in the other samples (HGPIN = 7.45, HB = 0.47, and BPH = 0.12). We show that SFRP2 hypermethylation is a common event in prostate cancer. SFRP2 methylation in combination with other epigenetic markers may be a useful biomarker of prostate cancer.This publication has 49 references indexed in Scilit:
- NCBI GEO: archive for functional genomics data sets--10 years onNucleic Acids Research, 2010
- Blocking Wnt signaling by SFRP-like molecules inhibits in vivo cell proliferation and tumor growth in cells carrying active β-cateninOncogene, 2010
- Evidence for field cancerization of the prostateThe Prostate, 2009
- Secreted Frizzled-related protein-1 is a negative regulator of androgen receptor activity in prostate cancerBritish Journal of Cancer, 2009
- Crosstalk between the Androgen Receptor and β-Catenin in Castrate-Resistant Prostate CancerCancer Research, 2008
- Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancerMolecular Cancer, 2008
- Regulation of Epithelial Branching Morphogenesis and Cancer Cell Growth of the Prostate by Wnt SignalingPLOS ONE, 2008
- Frequent epigenetic inactivation of Wnt antagonist genes in breast cancerBritish Journal of Cancer, 2008
- In silico mining identifies IGFBP3 as a novel target of methylation in prostate cancerBritish Journal of Cancer, 2007
- Function and biological roles of the Dickkopf family of Wnt modulatorsOncogene, 2006